Vertex
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Vertex, Inc. specializes in delivering advanced tax technology solutions to corporations across various sectors, including retail, communication, leasing, and manufacturing. These services are provide...
Latest News
19 hours ago · marketbeat.com
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts LoomVertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event.
3 days ago · seekingalpha.com
Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On ItMaze Therapeutics, Inc. is positioned as the only APOL1 inhibitor competitor to Vertex, with strong Phase 2 data and funding into 2029. MAZE's HORIZON trial showed robust uACR reductions, especially in non-diabetic and severe FSGS patients, supporting a pivotal trial in these populations. Vertex's AMPLITUDE results and market-building efforts de-risk MAZE's path, offering regulatory precedent and commercial infrastructure for APOL1-mediated kidney disease.
5 days ago · fool.com
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis therapies.
6 days ago · globenewswire.com
Only One in Six Enterprises Treats Indirect Tax as a Standing Board ItemKING OF PRUSSIA, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released the 2026 Vertex CompOps™ Index, a global study of how enterprises govern indirect tax and compliance, and how closely tax, IT, and finance work together to run it.
8 days ago · zacks.com
Here is Why Growth Investors Should Buy Vertex (VERX) NowVertex (VERX) could produce exceptional returns because of its solid growth attributes.
10 days ago · fool.com
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while diversifying into gene editing and treatments for acute pain.
11 days ago · fool.com
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 YearsVertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.
12 days ago · marketbeat.com
What Vertex (VERX) Said on Its Q3 Earnings CallVertex NASDAQ: VERX raised its full-year revenue and earnings guidance after reporting third-quarter revenue growth of 11% and a nearly 50% increase in adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA.
12 days ago · seekingalpha.com
Vertex, Inc. (VERX) Q3 2026 Earnings Call TranscriptVertex, Inc. (VERX) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Vertex (VERX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VERX